Molecular Partners (NASDAQ:MOLN) Shares Up 3.1% – Here’s What Happened

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN)’s share price shot up 3.1% on Monday . The company traded as high as $4.43 and last traded at $4.36. 1,977 shares were traded during trading, a decline of 53% from the average session volume of 4,198 shares. The stock had previously closed at $4.23.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. JPMorgan Chase & Co. dropped their target price on Molecular Partners from $4.00 to $3.75 and set a “neutral” rating on the stock in a research report on Monday, December 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Molecular Partners in a research note on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $7.88.

Molecular Partners Trading Up 3.4%

The firm has a market cap of $179.49 million, a PE ratio of -2.32 and a beta of 1.08. The company has a 50 day moving average price of $4.17 and a 200 day moving average price of $3.87.

Molecular Partners (NASDAQ:MOLN) last issued its quarterly earnings data on Thursday, October 30th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.05. As a group, equities research analysts anticipate that Molecular Partners AG Sponsored ADR will post -1.93 earnings per share for the current fiscal year.

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.